Another step toward sickle cell disease treatment

July 10, 2014 by Eric Peters
Martin Safo, Ph.D., and Richmond Danso-Danquah, Ph.D.

(Medical Xpress)—A compound discovered at Virginia Commonwealth University has taken yet another step closer to becoming the only approved drug in the world that is therapeutically effective in managing adult sickle cell disease by targeting hemoglobin.

Named Aes-103, the compound is the focus of the lead program at AesRx, a biopharmaceutical company dedicated to the development of novel drugs. It was announced this week that AesRx was purchased by Baxter International, a global health care company with expertise in medical devices, pharmaceuticals and biotechnology.

"This is so important that I cannot underestimate its value," said Donald Abraham, Ph.D., Alfred and Frances P. Burger Emeritus Professor of Medicinal Chemistry and Biological Chemistry at VCU, who is an original developer of the compound. "Without this financial support, the advanced would have taken many years longer."

The compound, originally patented by VCU under the name 5-HMF, was developed by a team from the VCU Institute for Structural Biology and Drug Discovery, an interdisciplinary research center spanning the School of Medicine and the School of Pharmacy. The team included Martin Safo, Ph.D., associate professor of ; Richmond Danso-Danquah, Ph.D., assistant professor of medicinal chemistry; and Abraham, emeritus director of the institute.

Relabeled as Aes-103, the compound was licensed by VCU Innovation Gateway to AesRx - a startup company at the time - which began clinical trials.

"We are very grateful for the role VCU has played in the development of Aes-103," said Steve Seiler, AesRx founder and CEO. "As a small company focusing on a big unmet medical need, AesRx needed to be pragmatic in its development strategy for Aes-103 and adjust as new data and financing strategies emerged. VCU worked collaboratively with us on this effort and was a true partner with AesRx all along the way."

VCU's liason to the company has been VCU Innovation Gateway, a university resource that facilitates commercialization of university inventions and supports university research through collaborative agreements.

"Without Innovation Gateway at VCU, and the efforts of our former president Dr. Eugene Trani and his establishment of the Biotechnology Research Park, this invention would have never reached clinical trials," Abraham said. "I am very grateful to have had the opportunity for our basic research to be translated into a potentially useful compound for the treatment of ."

The Aes-103 program is currently in a Phase 2 clinical trial as part of an ongoing collaboration with the NIH's National Center for Advancing Translational Sciences (NCATS) through its Therapeutics for Rare and Neglected Diseases (TRND) program.

Sickle cell disease is a recessive disorder of the hemoglobin that can lead to a wide range of serious, sometimes life-threatening conditions, including chronic hemolytic anemia, chronic pain and acute painful crisis, stroke, acute chest syndrome and cumulative damage to tissues and organs. More than 100,000 people in the United States are afflicted with .

Aes-103 is a first-in-class, oral, small molecule compound. Early studies indicate the compound may work by binding to and stabilizing the relaxed state of hemoglobin and increasing oxygen affinity and stabilization, thereby reducing the sickling of red blood cells which, in turn, may reduce sickling-related outcomes such as vaso-occlusive crisis, pain, severe anemia and fatigue.

Explore further: Research leads to possible new treatment for sickle cell disease

Related Stories

Research leads to possible new treatment for sickle cell disease

September 23, 2013
There's a new ray of hope for those battling sickle cell disease thanks to a compound that was discovered at Virginia Commonwealth University.

First drug candidate from NIH program acquired by biopharmaceutical company

July 9, 2014
A drug candidate developed by researchers at the NIH's National Center for Advancing Translational Sciences (NCATS) and its collaborators to treat sickle cell disease has been acquired by Baxter International's BioScience ...

New compound discovered that rapidly kills liver cancer

March 14, 2012
Scientists have identified a new compound that rapidly kills hepatocellular carcinoma (HCC) cells, the most common form of liver cancer and fifth most common cancer worldwide, while sparing healthy tissue. The compound, Factor ...

Novel therapy helps ease pain and suffering for sickle cell patients

September 25, 2012
Chronic, debilitating pain and potential organ failure are what approximately 100,000 sickle cell patients in the United States live with each day. Yutaka Niihara, M.D., M.P.H. - lead investigator at The Los Angeles Biomedical ...

Researchers reveal potential treatment for sickle cell disease

November 2, 2011
A University of Michigan Health System laboratory study reveals a key trigger for producing normal red blood cells that could lead to a new treatment for those with sickle cell disease.

Recommended for you

Want to win at sports? Take a cue from these mighty mice

July 20, 2017
As student athletes hit training fields this summer to gain the competitive edge, a new study shows how the experiences of a tiny mouse can put them on the path to winning.

'Smart' robot technology could give stroke rehab a boost

July 19, 2017
Scientists say they have developed a "smart" robotic harness that might make it easier for people to learn to walk again after a stroke or spinal cord injury.

Engineered liver tissue expands after transplant

July 19, 2017
Many diseases, including cirrhosis and hepatitis, can lead to liver failure. More than 17,000 Americans suffering from these diseases are now waiting for liver transplants, but significantly fewer livers are available.

Lunatic Fringe gene plays key role in the renewable brain

July 19, 2017
The discovery that the brain can generate new cells - about 700 new neurons each day - has triggered investigations to uncover how this process is regulated. Researchers at Baylor College of Medicine and Jan and Dan Duncan ...

New animal models for hepatitis C could pave the way for a vaccine

July 19, 2017
They say that an ounce of prevention is worth a pound of cure. In the case of hepatitis C—a disease that affects nearly 71 million people worldwide, causing cirrhosis and liver cancer if left untreated—it might be worth ...

Omega-3 fatty acids fight inflammation via cannabinoids

July 18, 2017
Chemical compounds called cannabinoids are found in marijuana and also are produced naturally in the body from omega-3 fatty acids. A well-known cannabinoid in marijuana, tetrahydrocannabinol, is responsible for some of its ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.